 BioLineRx Ltd. NASDAQ: BLRX, TASE: BLRX, a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office USPTO for a patent application claiming the use of motixafortide BL-8040, a novel immunotherapy compound, combined with any PD-1 inhibitor, for the treatment of any type of cancer. 